CD274 and neoplasm: ICIs, such as PD-1 inhibitors (e.g., nivolumab, pembrolizumab) and PD-L1 inhibitors (e.g., atezolizumab), block these interactions, restore T cell function, and enable them to identify and kill tumor cells [102,103].